Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy

AIDS

Volumn 30, Issue 7, 2016, Pages 1027-1038

  Schouten, Judith ^a   Su, Tanja ^b   Wit, Ferdinand W ^a,c   Kootstra, Neeltje A ^b   Caan, Matthan W A ^b   Geurtsen, Gert J ^a   Schmand, Ben A ^a,d   Stolte, Ineke G ^c,e   Prins, Maria ^c,e   Majoie, Charles B ^b   Portegies, Peter ^a,f   Reiss, Peter ^a,c,g  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Trinity Building C ^*  (United States)

^c Internal Medicine Division of Infectious Diseases Center for Infection and Immunity Amsterdam   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^f ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^g STICHTING HIV MONITORING   (Netherlands)

Author keywords

cognitive impairment; determinants; HIV infection; HIV associated neurocognitive disorders; risk factors

Indexed keywords

ANTIRETROVIRUS AGENT; CANNABIS;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANNABIS USE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; COGNITION ASSESSMENT; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT DURATION; VIREMIA; WAIST HIP RATIO; CANNABIS ADDICTION; COGNITIVE DYSFUNCTION; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; PROSPECTIVE STUDY; RISK FACTOR;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; COGNITIVE DYSFUNCTION; DEPRESSION; HIV INFECTIONS; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84954495812     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001017     Document Type: Article

References (56)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol 2013; 177:116-125.
3. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14:195-207.
4. Cysique LA, Brew BJ. Prevalence of nonconfounded HIV-asso-ciated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 2011; 17:176-183.
5. Winston A, Arenas-Pinto A, Stöhr W, Fisher M, Orkin CM, Aderogba K, et al. Neurocognitive function in HIV infected patients on antiretroviral therapy. PLoS One 2013; 8:e61949.
6. Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS Lond Engl 2011; 25:561-575.
7. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS Lond Engl 2007; 21:1915-1921.
8. Simioni S, Cavassini M, Annoni J-M, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS Lond Engl 2010; 24:1243-1250.
9. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75:2087-2096.
10. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neuro-cognitive disorders. Neurology 2007; 69:1789-1799.
11. Su T, Schouten J, Geurtsen GJ, Wit FW, Stolte IG, Prins M, et al. Multivariate normative comparison, a novel method for more reliably detecting cognitive impairment in HIV infection. AIDS Lond Engl 2015; 29:547-557.
12. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17:3-16.
13. Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect Dis 2013; 13:976-986.
14. Schouten J, Wit FW, Stolte IG, Kootstra N, van der Valk M, Geerlings SG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV Cohort Study. Clin Infect Dis Off Publ Infect Dis Soc Am 2014; 59:1787-1797.
15. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck depression inventories-IA and-II in psychiatric outpatients. J Pers Assess 1996; 67:588-597.
16. Beck A, Ward C, Mendelson M, Mochk J, Erbaugh J.Assessment of depression: the depression inventory. Arch Gen Psychiatry 1961; 4:561-571.
17. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol Br Psychol Soc 1982; 21 (Pt 1):1-16.
18. Lawton M, Brody E. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1982; 9:179-186.
19. Schmand B, Lindeboom J, van Harskamp F. Dutch adult reading test. Lisse: Swets en Zeitlinger; 1992.
20. Huizenga HM, Smeding H, Grasman RPPP, Schmand B. Multi-variate normative comparisons. Neuropsychologia 2007; 45:2534-2542.
21. Thames AD, Arbid N, Sayegh P. Cannabis use and neurocog-nitive functioning in a nonclinical sample of users. Addict Behav 2014; 39:994-999.
22. Cristiani SA, Pukay-Martin ND, Bornstein RA. Marijuana use and cognitive function in HIV-infected people. J Neuropsy-chiatry Clin Neurosci 2004; 16:330-335.
23. Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev 2013; 4:CD005175.
24. Hazekamp A, Heerdink ER. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. Eur J Clin Pharmacol 2013; 69:1575-1580.
25. Lorius N, Locascio JJ, Rentz DM, Johnson KA, Sperling RA, Viswanathan A, et al. Vascular disease and risk factors are associated with cognitive decline in the Alzheimer disease spectrum. Alzheimer Dis Assoc Disord 2015; 29:18-25.
26. Raffaitin C, Féart C, Le Goff M, Amieva H, Helmer C, Akbaraly TN, et al. Metabolic syndrome and cognitive decline in French elders: the Three-City Study. Neurology 2011; 76:518-525.
27. Reijmer YD, van den Berg E, Dekker JM, Nijpels G, Stehouwer CDA, Kappelle LJ, et al. Development of vascular risk factors over 15 years in relation to cognition: the Hoorn Study. J Am Geriatr Soc 2012; 60:1426-1433.
28. Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010; 75:864-873.
29. Bordier L, Doucet J, Boudet J, Bauduceau B. Update on cognitive decline and dementia in elderly patients with diabetes. Diabetes Metab 2014; 40:331-337.
30. Ganguli M, Fu B, Snitz BE, Hughes TF, Chang C-CH. Mild cognitive impairment: incidence and vascular risk factors in a population-based cohort. Neurology 2013; 80:2112-2120.
31. Fabbiani M, Ciccarelli N, Tana M, Farina S, Baldonero E, Di Cristo V, et al. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. HIV Med 2013; 14:136-144.
32. Valcour VG, Shikuma CM, Shiramizu BT, Williams AE, Watters MR, Poff PW, et al. Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J Acquir Immune Defic Syndr 1999 2005; 38:31-36.
33. Sanz CM, Ruidavets J-B, Bongard V, Marquié J-C, Hanaire H, Ferrières J, et al. Relationship between markers of insulin resistance, markers of adiposity, HbA1c, and cognitive functions in a middle-aged population-based sample: the MONA LISA study. Diabetes Care 2013; 36:1512-1521.
34. Crichton GE, Elias MF, Buckley JD, Murphy KJ, Bryan J, Frisardi V. Metabolic syndrome, cognitive performance, and dementia. J Alzheimers Dis 2012; 30:S77-S87.
35. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, Letendre SL, Ellis RJ, Heaton RK, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology 2012; 78:485-492.
36. Weinstein G, Goldbourt U, Tanne D. Angina pectoris severity among coronary heart disease patients is associated with subsequent cognitive impairment. Alzheimer Dis Assoc Disord 2015; 29:6-11.
37. Reis JP, Launer LJ, Terry JG, Loria CM, Zeki Al Hazzouri A, Sidney S, et al. Subclinical atherosclerotic calcification and cognitive functioning in middle-aged adults: the CARDIA study. Atherosclerosis 2013; 231:72-77.
38. Becker JT, Kingsley L, Mullen J, Cohen B, Martin E, Miller EN, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 2009; 73:1292-1299.
39. Anand S, Johansen KL, Tamura MK. Aging and chronic kidney disease: the impact on physical function and cognition. J Gerontol A Biol Sci Med Sci 2014; 69A:315-322.
40. Kalayjian RC, Wu K, Evans S, Clifford DB, Pallaki M, Currier JS, et al. Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals. J Acquir Immune Defic Syndr 1999 2014; 67:30-35.
41. Cysique LA, Moffat K, Moore DM, Lane TA, Davies NWS, Carr A, et al. HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study. PloS One 2013; 8:e61738.
42. Nakamoto BK, Jahanshad N, McMurtray A, Kallianpur KJ, Chow DC, Valcour VG, et al. Cerebrovascular risk factors and brain microstructural abnormalities on diffusion tensor images in HIV-infected individuals. J Neurovirol 2012; 18:303-312.
43. McMurtray A, Nakamoto B, Shikuma C, Valcour V. Small-vessel vascular disease in human immunodeficiency virus infection: the Hawaii aging with HIV cohort study. Cerebrovasc Dis Basel Switz 2007; 24:236-241.
44. McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety 2013; 30:515-527.
45. Malaspina L, Woods SP, Moore DJ, Depp C, Letendre SL, Jeste D, et al. Successful cognitive aging in persons living with HIV infection. J Neurovirol 2011; 17:110-119.
46. Cysique LA, Deutsch R, Atkinson JH, Young C, Marcotte TD, Dawson L, et al. Incident major depression does not affect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc 2007; 13:1-11.
47. Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS Lond Engl 2011; 25:1747-1751.
48. Garvey L, Surendrakumar V, Winston A. Low rates of neuro-cognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials 2011; 12:333-338.
49. McCombe JA, Vivithanaporn P, Gill MJ, Power C. Predictors of symptomatic HIV-associated neurocognitive disorders in universal healthcare. HIV Med 2013; 14:99-107.
50. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
51. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev 2013; 254:326-342.
52. Zanni MV, Schouten J, Grinspoon SK, Reiss P. Risk of coronary heart disease in patients with HIV infection. Nat Rev Cardiol 2014; 11:728-741.
53. Letendre SL, Fitzsimons CA, Ellis RJ, Clifford D, Collier AC, Gelman B, et al. Correlates of CSF viral loads in 1221 volunteers of the CHARTER Cohort. 17th Conference on Retroviruses and Opportunistic Infections, 16-19 February 2010, San Francisco, California; abstract 172.
54. Hildebrandt VH, Ooijendijk WTM, Hopman-Rock M (Eds): Trendrapport Bewegen en Gezondheid 2004-2005. Leiden: TNO, 2007.
55. American Diabetes Association. Diagnosis classification of diabetes mellitus. Diabetes Care 2012; 35 (Suppl 1):S64-S71.
56. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves JW, Hill MN, et al. Recommendations for blood pressure measurement in humans: anAHA scientific statement from the Councilon High Blood Pressure Research Professional and Public Education Subcommittee. J Clin Hypertens Greenwich Conn 2005; 7:102-109.